CVS Health Corporation $CVS Shares Purchased by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings Inc. raised its stake in CVS Health by 19.3% during Q3 to 384,548 shares (about $28.99 million), and other institutions also increased positions leaving hedge funds and institutional investors owning roughly 80.66% of the company.
• CVS beat Q4 estimates with $1.09 EPS (vs. $1.00 consensus) and revenue of $105.69 billion (+8.2% YoY), gave FY2026 guidance of 5.94–6.14 EPS, and has an average analyst rating of "Moderate Buy" with a $94.77 price target.
• The stock recently traded around $80.57, has a 12‑month range of $58.35–$85.15 and a $102.5 billion market cap; it pays a $0.665 quarterly dividend (3.3% yield) but shows a high payout ratio of 192.75%.

Crossmark Global Holdings Inc. raised its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 19.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 384,548 shares of the pharmacy operator's stock after buying an additional 62,305 shares during the period. Crossmark Global Holdings Inc.'s holdings in CVS Health were worth $28,991,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CVS. KCM Investment Advisors LLC boosted its position in CVS Health by 41.6% during the 3rd quarter. KCM Investment Advisors LLC now owns 19,220 shares of the pharmacy operator's stock worth $1,449,000 after purchasing an additional 5,649 shares during the period. Advisory Alpha LLC lifted its stake in shares of CVS Health by 13.4% during the third quarter. Advisory Alpha LLC now owns 5,068 shares of the pharmacy operator's stock worth $393,000 after purchasing an additional 600 shares in the last quarter. IFG Advisory LLC boosted its position in shares of CVS Health by 222.5% in the third quarter. IFG Advisory LLC now owns 45,101 shares of the pharmacy operator's stock worth $3,400,000 after buying an additional 31,116 shares during the period. Varenne Capital Partners acquired a new stake in shares of CVS Health in the third quarter valued at about $9,948,000. Finally, Fiduciary Group LLC acquired a new position in CVS Health during the 3rd quarter worth approximately $201,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

CVS stock opened at $80.57 on Thursday. The stock's 50 day simple moving average is $78.53 and its 200 day simple moving average is $77.50. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The firm has a market cap of $102.50 billion, a P/E ratio of 58.38, a P/E/G ratio of 0.84 and a beta of 0.49. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. During the same period last year, the firm posted $1.19 EPS. The company's revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.3%. CVS Health's dividend payout ratio is 192.75%.

Analyst Ratings Changes

Several brokerages have issued reports on CVS. UBS Group reaffirmed an "outperform" rating on shares of CVS Health in a research report on Wednesday, December 10th. TD Cowen raised their price target on shares of CVS Health from $100.00 to $105.00 and gave the company a "buy" rating in a report on Wednesday, December 10th. Sanford C. Bernstein reiterated a "market perform" rating and issued a $91.00 price objective on shares of CVS Health in a report on Tuesday, January 6th. Truist Financial set a $100.00 target price on CVS Health in a research note on Wednesday, December 10th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of CVS Health in a research note on Monday, December 29th. Nineteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $94.77.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.